Chemosensitization to carboplatin and paclitaxel by IAP inhibitor Debio 1143 in ovarian cancer cell lines: Signature identification for potential patient stratification
Rechavi-Robinson, D, Wiedemann, N, Schusterbauer, C, Rigotti, S, Brichory, F, Vuagniaux, G
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY
Levy, M. Y., Grudeva‐Popova, Z., Trneny, M., Jurczak, W., Pylypenko, H., Jagadeesh, D., Andre, M., Nasta, S., Rechavi‐Robinson, D., Toffanin, S., Micallef, S., Attinger, A., Rouits, E., Dymkowska, M., Nauwelaerts, H., Woei‐A‐Jin, F. J. S. H.
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
POSC370 Health-Related Quality of Life of Naratuximab Emtasine + Rituximab (N+R) in Second Line and Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): An Analysis of the Functional Assessment of Cancer Therapy Lymphoma (FACT-LYM) Measure and Mapped EQ-5D Values from a Phase II Trial
Orfanos, P, Peipert, J, Cella, D, Rechavi-Robinson, D, Gandola, A, Micallef, S, Brachet, S, Dymkowska, M
Published in Value in health (01.01.2022)
Published in Value in health (01.01.2022)
Get full text
Journal Article
408 - Chemosensitization to carboplatin and paclitaxel by IAP inhibitor Debio 1143 in ovarian cancer cell lines: Signature identification for potential patient stratification
Rechavi-Robinson, D., Wiedemann, N., Schusterbauer, C., Rigotti, S., Brichory, F., Vuagniaux, G.
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article